Chronic Pain and Depression: How They Interact

Pain and depression share more machinery than either condition shares with anything else. The same neurotransmitter systems, the same brain regions, the same descending pathways from brain to spinal cord. That overlap explains why each makes the other worse, and why one class of drug treats both — though not for the reason most people assume when they are offered it.

It also creates a specific and avoidable problem. Being offered an antidepressant for pain is regularly heard as being told the pain is imaginary, and a great many people decline treatment that would have helped because of that misunderstanding.

🔗 How they feed each other

The relationship runs in both directions, which is why it becomes self-sustaining.

Pain leads to depression through loss — of sleep, work, income, activity, independence, social contact, and the sense of a future that resembles the past. Persistent pain is exhausting in a way that is difficult to convey to anyone who has not experienced it, and the losses accumulate quietly.

Depression worsens pain measurably. It lowers pain thresholds, increases the attention paid to bodily sensation, reduces activity which leads to deconditioning and more pain, disrupts sleep which amplifies pain further, and removes the motivation required for rehabilitation.

The biology overlaps. Serotonin and noradrenaline are central to mood regulation and are also the transmitters of the descending inhibitory pathways — the system by which the brain turns pain signals down before they reach consciousness. When that system is weakened, more signal gets through. This is why drugs acting on both transmitters relieve pain, and why drugs acting on serotonin alone do so considerably less well.

🔬 Three kinds of pain

Modern pain medicine distinguishes three mechanisms, and treatment differs substantially between them. Getting this wrong is a common reason for treatment failure.

That third category is the one that causes the most distress, because investigations come back normal and people are told nothing is wrong. What is actually happening is central sensitisation — the nervous system itself has become amplified. Pain signals are turned up, non-painful sensations register as painful, and the pain spreads beyond any original site.

This is a measurable neurophysiological state, not a figure of speech. It is real pain produced by a real mechanism, and the fact that a scan looks normal is a statement about the scan rather than about the person. Understanding this changes the treatment approach entirely, since anti-inflammatories and opioids work poorly here while drugs acting on central pain processing work considerably better.

🩺 Recognising depression alongside pain

Diagnosis is complicated by overlap: fatigue, disturbed sleep, poor concentration and reduced appetite belong to both conditions, so counting symptoms overstates depression in someone with pain.

The features that discriminate better are the ones pain does not usually produce:

• Loss of pleasure in things that were still enjoyable despite the pain
• Feelings of worthlessness or excessive guilt
• Hopelessness about the future, beyond realistic concern about the pain
• Persistent low mood present most of the day, most days, rather than fluctuating with pain levels
• Thoughts of death or self-harm

A questionnaire such as the PHQ-9 is often used and is useful for tracking change, though it too counts symptoms that pain produces independently.

💊 Medication that treats both

Certain antidepressants relieve pain directly, and the choice depends on which pain mechanism is present.

The pattern is consistent: drugs acting on both serotonin and noradrenaline relieve pain, and drugs acting on serotonin alone largely do not. This reflects the biology of the descending inhibitory pathway and is worth knowing, because someone prescribed an SSRI who expected pain relief will be disappointed for a reason that has nothing to do with the drug being wrong for depression.

📏 Doses for pain are different

This point is worth its own section because it changes how the treatment is understood and how side effects are experienced.

Amitriptyline for pain typically starts at a very low dose taken at night and is increased slowly to a level well below what would be used for depression. Many people get pain benefit at doses a fraction of the antidepressant range.

Duloxetine is used within a similar range for both, which is part of why it suits people who have both conditions.

Two consequences follow. Side effects at pain doses are generally milder than the prescribing information suggests, since that information describes higher doses. And someone told the tablet is an antidepressant, who then reads about it, may be alarmed by a description that does not apply to what they have been given.

Timing also matters: sedating agents are taken a couple of hours before bed rather than at bedtime, since morning grogginess is the commonest reason people abandon them and shifting the timing usually resolves it.

🧪 Other medication for pain

Gabapentin and pregabalin have good evidence in neuropathic pain and considerably weaker evidence in non-neuropathic pain, where they are nonetheless widely prescribed. They cause drowsiness, dizziness and weight gain, have recognised misuse potential and a withdrawal syndrome, and are increasingly controlled. Where they help they are valuable; where they are being taken for pain that is not neuropathic, a review is worthwhile.

Anti-inflammatories work well for inflammatory and nociceptive pain and poorly for neuropathic and nociplastic pain. Long-term use carries stomach, kidney and cardiovascular risks.

Paracetamol is safe and its effect in chronic conditions is modest.

Opioids require an honest account. They work well for acute pain and cancer pain. For chronic non-cancer pain, long-term trial evidence is poor: benefit is small on average and diminishes with time, while harms accumulate — tolerance, dependence, constipation, hormonal suppression, increased falls, and a phenomenon called opioid-induced hyperalgesia in which the drug itself increases pain sensitivity. They also worsen depression over time and interact dangerously with alcohol and sedatives.

This does not mean nobody should take them. It means the expectation of long-term benefit should be modest, doses should be kept low, and a plan to review is part of starting rather than an afterthought.

Topical treatments — capsaicin, lidocaine patches, topical anti-inflammatories — deliver useful relief for localised pain with far less systemic exposure and are under-used.

🧠 The psychological treatments that work

These are frequently offered in a way that implies the pain is not physical, which guarantees rejection. Presented accurately, they are among the better-evidenced interventions available.

Cognitive behavioural therapy for pain does not aim to convince anyone the pain is imaginary. It works on the relationship between pain, thought, mood and behaviour — reducing avoidance, restoring activity, breaking the cycle in which fear of pain produces inactivity which produces more pain.

Pain catastrophising is the strongest psychological predictor of outcome in chronic pain, and it is modifiable. It describes a pattern of magnifying the threat, ruminating on the sensation and feeling helpless about it — and it measurably increases experienced pain intensity through effects on the nervous system, not through imagination. Addressing it directly reduces pain.

Acceptance and commitment therapy takes a different route, working on living according to what matters while the pain is present rather than waiting for it to resolve first. It has good evidence in conditions where complete relief is not achievable.

Pain management programmes combine education, graded activity, psychological work and medication review, usually in groups. Group format is not a cost compromise: much of the benefit comes from being among people who do not need the pain explained to them.

🏃 Activity and pacing

Exercise improves pain, function and mood across most chronic pain conditions, and the type matters less than consistency. The obstacle is that increased activity often increases pain temporarily, which is read as damage.

Pacing addresses this. The common pattern is the boom-and-bust cycle: on a good day the person does everything that has accumulated, pays for it over the following days, rests, and repeats. Over time the good days shrink.

Pacing means working to a level that can be sustained daily, including on good days when it feels unnecessary, and increasing gradually and deliberately rather than opportunistically. It is genuinely difficult to accept, because it involves doing less than you could on the days you feel able.

Graded activity builds from that baseline in small planned increments over weeks, based on the schedule rather than on how the pain feels on any given day.

😴 Sleep, the third element

Pain, depression and insomnia form a triangle in which each worsens the other two, and sleep is frequently the most tractable of the three.

The relationship with pain is bidirectional and the direction that surprises people is that poor sleep increases pain more reliably than pain disturbs sleep. Experimental sleep restriction lowers pain thresholds in healthy volunteers within days.

The most effective treatment is cognitive behavioural therapy for insomnia, which outperforms sleeping tablets and works in people with chronic pain specifically. Sedating antidepressants used for pain deliver a useful double effect here, which is one reason amitriptyline at night suits people whose pain and sleep are both problems.

Sleeping tablets are a poor long-term solution: tolerance, dependence, next-day impairment and increased falls, with no effect on pain.

🗣️ Being taken seriously

Something worth saying directly, because it affects whether people accept treatment at all.

People with chronic pain, particularly the nociplastic kind where investigations are normal, frequently report being disbelieved. Conditions such as fibromyalgia have a long history of being dismissed. Women report this more often than men, and studies of pain assessment have documented systematic differences in how pain reports are treated.

The consequences are practical: people stop reporting symptoms, avoid appointments, and refuse psychological or antidepressant treatment because accepting it feels like conceding that the pain was never real.

The accurate position is that pain is always real. Its mechanism may be tissue damage, nerve damage or altered central processing, and all three produce genuine pain. Treatment aimed at the nervous system is treatment of the mechanism, not a verdict on the patient.

📋 A practical approach

Establish the pain mechanism, since it determines which treatments have a chance of working. Nociceptive, neuropathic and nociplastic pain respond to quite different things.

Screen for depression properly, using the features that distinguish it from pain rather than the overlapping ones, and treat it where present because untreated depression makes pain worse and rehabilitation impossible.

Choose medication that addresses both where both are present — duloxetine most directly, or a tricyclic at low dose where sleep is also disrupted.

Set realistic goals. A thirty per cent reduction in pain is considered a meaningful clinical response, and complete relief is usually not achievable in long-standing pain. Aiming for function rather than for a pain score of zero produces better outcomes and less disappointment.

Treat sleep directly rather than assuming it will improve when the pain does.

Keep moving, with pacing, and expect a temporary increase in symptoms that does not indicate damage.

Ask about a pain management programme, which combines the elements above and is under-referred.

Review medication periodically, particularly opioids and gabapentinoids, since drugs started for a good reason accumulate and continue long after they stopped helping.

Medication addressing both pain and mood is stocked in the antidepressants category, including Cymbalta (duloxetine), which is licensed for depression and for several chronic pain conditions, and Elavil (amitriptyline), long used at low doses for nerve pain. Both require assessment and gradual dose adjustment.

❓ Frequently asked questions

📑 Sources and editorial

• IASP definitions of nociceptive, neuropathic and nociplastic pain
• NICE guidance on chronic pain in over 16s and on neuropathic pain in adults
• Cochrane reviews of duloxetine, amitriptyline and other antidepressants for neuropathic pain and fibromyalgia
• Evidence reviews on long-term opioid therapy for chronic non-cancer pain
• Sullivan MJL and colleagues — pain catastrophising and its relationship to pain outcomes
• Research on experimental sleep restriction and pain threshold
• Studies of suicide risk in chronic pain populations
• FDA prescribing information for duloxetine, amitriptyline and nortriptyline
• Related reading: generalised anxiety disorder
• Related products: antidepressants category, pain medication category
• RXshop Editorial Team — reviewed by Thomas Walsh, MD, Psychiatry